Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность сперматопротективной терапии на основе Селцинка плюс у больных туберкулезом предстательной железы
Эффективность сперматопротективной терапии на основе Селцинка плюс у больных туберкулезом предстательной железы
Кульчавеня Е.В., Осадчий А.В. Эффективность сперматопротективной терапии на основе Селцинка плюс у больных туберкулезом предстательной железы. Consilium Medicum. 2016; 18 (7): 22–26. DOI: 10.26442/2075-1753_2016.7.22-26
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Введение. Туберкулез половых органов приводит к нарушению репродуктивной функции. Учитывая, что у 77% мужчин, умерших от туберкулеза всех локализаций, при аутопсии был диагностирован туберкулез предстательной железы (ПЖ), актуальность проблемы высока.
Цель исследования – разработать и апробировать способ восстановления/сохранения фертильности больных туберкулезом ПЖ и оценить его эффективность.
Материал и методы. Проведено открытое проспективное сравнительное рандомизированное исследование, в которое были включены 72 больных туберкулезом ПЖ. Пациенты основной группы (n=49) получали стандартное противотуберкулезное лечение в комплексе с патогенетической сперматопротективной терапией, включавшей Селцинк плюс и хорионический гонадотропин. В группе сравнения (n=23) мужчины получали только этиотропное противотуберкулезное лечение.
Результаты. Противотуберкулезная химиотерапия оказала негативное влияние на эякулят: 2-месячный прием препаратов в группе сравнения обусловил уменьшение числа сперматозоидов на 23,9%, числа активно подвижных форм сперматозоидов – на 10,6%, числа нормальных спермиев – на 32,3%. Проведение патогенетической сперматопротективной терапии способствовало увеличению числа сперматозоидов на 47,8%, числа активно подвижных форм сперматозоидов (суммарно группы А и В) – на 40,5%, количества нормальных форм спермиев – на 41,9%.
Выводы. Сперматопротективная терапия, включающая Селцинк плюс и хорионический гонадотропин, позволяет достоверно повысить фертильность эякулята. Необходим длительный прием препаратов для предотвращения негативных последствий туберкулезного воспаления и противотуберкулезной терапии в отношении сперматогенеза.
Ключевые слова: туберкулез предстательной железы, химиотерапия, селен, цинк, Селцинк, бесплодие, спермограмма, эякулят, урогенитальный туберкулез, противотуберкулезная терапия, простатит, патогенетическая терапия.
Цель исследования – разработать и апробировать способ восстановления/сохранения фертильности больных туберкулезом ПЖ и оценить его эффективность.
Материал и методы. Проведено открытое проспективное сравнительное рандомизированное исследование, в которое были включены 72 больных туберкулезом ПЖ. Пациенты основной группы (n=49) получали стандартное противотуберкулезное лечение в комплексе с патогенетической сперматопротективной терапией, включавшей Селцинк плюс и хорионический гонадотропин. В группе сравнения (n=23) мужчины получали только этиотропное противотуберкулезное лечение.
Результаты. Противотуберкулезная химиотерапия оказала негативное влияние на эякулят: 2-месячный прием препаратов в группе сравнения обусловил уменьшение числа сперматозоидов на 23,9%, числа активно подвижных форм сперматозоидов – на 10,6%, числа нормальных спермиев – на 32,3%. Проведение патогенетической сперматопротективной терапии способствовало увеличению числа сперматозоидов на 47,8%, числа активно подвижных форм сперматозоидов (суммарно группы А и В) – на 40,5%, количества нормальных форм спермиев – на 41,9%.
Выводы. Сперматопротективная терапия, включающая Селцинк плюс и хорионический гонадотропин, позволяет достоверно повысить фертильность эякулята. Необходим длительный прием препаратов для предотвращения негативных последствий туберкулезного воспаления и противотуберкулезной терапии в отношении сперматогенеза.
Ключевые слова: туберкулез предстательной железы, химиотерапия, селен, цинк, Селцинк, бесплодие, спермограмма, эякулят, урогенитальный туберкулез, противотуберкулезная терапия, простатит, патогенетическая терапия.
________________________________________________
Introduction. Tuberculosis of genitals leads to disruption of reproductive function. Given that 77% of men who died of tuberculosis in all locations, tuberculosis of the prostate (PT) was diagnosed at autopsy, the problem of high relevance. The purpose of research is to develop and test a way to restore/preserve fertility patients with pancreatic tuberculosis and to evaluate its effectiveness.
Material and methods. An open, prospective, comparative, randomized study in which 72 patients with pancreatic tuberculosis were included. Patients of the main group (n=49) received standard tuberculosis (TB) treatment in combination with pathogenetic spermatoprotektivnoy therapy include Selzink plus and chorionic gonadotropin. The comparison group (n=23) received only men etiotropic TB treatment.
Results. Treatment for TB had a negative effect on the ejaculate 2-month administration of drugs in the comparison group led to a decrease in sperm count of 23.9%, the number of actively motile sperm forms – by 10.6%, the number of normal spermatozoa – by 32.3%. Carrying sperm-protective pathogenetic therapy helped to increase the number of sperm by 47.8%, the number of active mobile forms of spermatozoa (total of A and B) – by 40.5%, the number of normal sperm forms – by 41.9%.
Conclusions. Sperm-protective therapy including Selzink plus and human chorionic gonadotropin, allows to significantly increase the fertility of an ejaculate. We need long-term use of drugs to prevent the negative effects of tuberculous inflammation and TB treatment in respect of spermatogenesis.
Key words: tuberculosis of the prostate, chemotherapy, selenium, zinc, Selzink, infertility, semen, ejaculate, urogenital tuberculosis, anti-tuberculosis therapy, prostatitis, pathogenetic therapy.
Material and methods. An open, prospective, comparative, randomized study in which 72 patients with pancreatic tuberculosis were included. Patients of the main group (n=49) received standard tuberculosis (TB) treatment in combination with pathogenetic spermatoprotektivnoy therapy include Selzink plus and chorionic gonadotropin. The comparison group (n=23) received only men etiotropic TB treatment.
Results. Treatment for TB had a negative effect on the ejaculate 2-month administration of drugs in the comparison group led to a decrease in sperm count of 23.9%, the number of actively motile sperm forms – by 10.6%, the number of normal spermatozoa – by 32.3%. Carrying sperm-protective pathogenetic therapy helped to increase the number of sperm by 47.8%, the number of active mobile forms of spermatozoa (total of A and B) – by 40.5%, the number of normal sperm forms – by 41.9%.
Conclusions. Sperm-protective therapy including Selzink plus and human chorionic gonadotropin, allows to significantly increase the fertility of an ejaculate. We need long-term use of drugs to prevent the negative effects of tuberculous inflammation and TB treatment in respect of spermatogenesis.
Key words: tuberculosis of the prostate, chemotherapy, selenium, zinc, Selzink, infertility, semen, ejaculate, urogenital tuberculosis, anti-tuberculosis therapy, prostatitis, pathogenetic therapy.
Полный текст
Список литературы
1. Кульчавеня Е.В., Брижатюк Е.В., Хомяков В.Т. Туберкулез экстраторакальных локализаций в Сибири и на Дальнем Востоке. Туберкулез и болезни легких. 2005; 6: 23–5./ Kulchavenya E.V., Brizhatiuk E.V., Khomiakov V.T. Tuberkulez ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2005; 6: 23–5. [in Russian]
2. Кульчавеня Е.В., Брижатюк Е.В., Ковешникова Е.Ю., Свешникова Н.Н. Новые тенденции в эпидемической ситуации по туберкулезу экстраторакальных локализаций в Сибири и на Дальнем Востоке. Туберкулез и болезни легких. 2009; 10: 27–31. / Kulchavenya E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
3. Жукова И.И., Кульчавеня Е.В., Холтобин Д.П. Туберкулез мочеполовой системы сегодня. Урология. 2013; 1: 13–6. / Zhukova I.I., Kulchavenya E.V., Kholtobin D.P. Tuberkulez mochepolovoi sistemy segodnia. Urologiia. 2013; 1: 13–6. [in Russian]
4. Goodarzi D, Cyrus A, Baghinia MR et al. The efficacy of zinc for treatment of chronic prostatitis. Acta Med Indones 2013; 45 (4): 259–64.
5. Ludwig M, Dimitrakov J, Diemer T et al. Prostatitis syndrome. Changes in the ejaculate and effects on fertility. Urologe A 2001; 40 (1): 18–23.
6. Cai T, Wagenlehner FM, Mondaini N et al. Effect of human papillomavirus and Chlamydia trachomatis co-infection on sperm quality in young heterosexual men with chronic prostatitis-related symptoms. BJU Int 2014; 113 (2): 281–7. doi: 10.1111/bju.12244
7. Ivanov IB, Gritsenko VA, Kuzmin MD. Phenotypic differences between coagulase-negative staphylococci isolated from seminal fluid of healthy men and men suffering from chronic prostatitis syndrome. Int J Androl 2010; 33 (3): 563–7. doi: 10.1111/j.1365-2605.2009.00969.x
8. Dohle GR. Inflammatory-associated obstructions of the male reproductive tract. Andrologia 2003; 35 (5): 321–4.
9. Zhao H, Shen JH, Chen YP et al. Changes of seminal parameters, zinc concentration and antibacterial activity in patients with non-inflammatory chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue 2008; 14 (6): 530–2.
10. Flibotte JJ, Lee GE, Buser GL et al. Infertility, in vitro fertilization and congenital tuberculosis. J Perinatol 2013; 33 (7): 565–8. doi: 10.1038/jp.2012.146
11. Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev 2013; 8: CD009071. doi: 10.1002/14651858.CD009071.pub2
12. Yanushpolsky EH, Politch JA, Hill JA, Anderson DJ. Is leukocytospermia clinically relevant? Fertil Steril 1996; 66 (5): 822–5.
13. Domes T, Lo KC, Grober ED et al. The incidence and effect of bacteriospermia and elevated seminal leukocytes on semen parameters. Fertil Steril 2012; 97 (5): 1050–5. doi: 10.1016/j.fertnstert.2012.01.124
14. Кульчавеня Е.В., Неймарк А.И. Простатит. Диагностика и лечение: руководство. М.: ГЭОТАР-Медиа, 2010. / Kulchavenya E.V., Neimark A.I. Prostatit. Diagnostika i lechenie: rukovodstvo. M.: GEOTAR-Media, 2010. [in Russian]
15. Kulchavenya E. Best practice in the diagnosis and management of Urogenital Tuberculosis. Ther Adv Urol 2013; 5 (3): 143–51. doi: 10.1177/1756287213476128
16. Кульчавеня Е.В., Бреусов А.А. Эффективность уро-ваксома при рецидивирующих инфекционно-воспалительных заболеваниях мочеполовой системы. Урология. 2011; 4: 7–11. / Kulchavenya E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
17. Mirone M, Giannetta E, Isidori AM. Selenium and reproductive function. A systematic review. J Endocrinol Invest 2013; 36 (10 Suppl): 28–36.
18. Walczak-Jedrzejowska R, Wolski JK, Slowikowska-Hilczer J. The role of oxidative stress and antioxidants in male fertility. Cent European J Urol 2013; 66 (1): 60–7. doi: 10.5173/ceju.2013.01.art19
19. Мохирева Л.В., Богадельникова И.В. Биологическая роль цинка в организме человека. Туберкулез и болезни легких. 2011; 7: 3–10. / Mokhireva L.V., Bogadel'nikova I.V. Biologicheskaia rol' tsinka v organizme cheloveka. Tuberkulez i bolezni legkikh. 2011; 7: 3–10. [in Russian]
20. Lombardo F, Fiducia M, Lunghi R et al. Effects of a dietary supplement on chronic pelvic pain syndrome (Category IIIA), leucocytospermia and semen parameters. Andrologia 2012; 44 (Suppl. 1): 672–8. doi: 10.1111/j.1439-0272.2011.01248.x
21. Witkowska-Zimny M, Gunerka A, Wietrak E et al. Verification of the effectiveness of the dietary supplementation in infertility treatment. Pol Merkur Lekarski 2013; 35 (210): 347–51.
22. Eslamian G, Amirjannati N, Rashidkhani B et al. Nutrient patterns and asthenozoospermia: a case-control study. Andrologia 2016. doi: 10.1111/and.12624. [Epub ahead of print]
23. Ansar S, Abudawood M, Hamed SS, Aleem MM. Sodium Selenite Protects Against Silver Nanoparticle-Induced Testicular Toxicity and Inflammation. Biol Trace Elem Res 2016. [Epub ahead of print]
24. Russo A, Capogrosso P, La Croce G et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf 2016 Jun 1: 1–10. [Epub ahead of print]
25. Zhu C, Ling Q, Cai Z et al. Selenium (Se) containing phycocyanin from Se-enriched Spirulina platensis reduces inflammation in DSS-induced colitis by inhibiting NF-κB activation. J Agric Food Chem 2016. [Epub ahead of print]
26. Amin KA, Hashem KS, Alshehri FS et al. Antioxidant and Hepatoprotective Efficiency of Selenium Nanoparticles Against Acetaminophen-Induced Hepatic Damage. Biol Trace Elem Res 2016. [Epub ahead of print]
27. Bierla K, Flis-Borsuk A, Suchocki P et al. Speciation of selenium in selenium-enriched sunflower oil by HPLC-ICP MS/electrospray – Orbitrap MS/MS. J Agric Food Chem 2016. [Epub ahead of print]
28. Sun JW, Shu XO, Li HL et al. Dietary selenium intake and mortality in two population-based cohort studies of 133 957 Chinese men and women. Public Health Nutr. 2016 May 20: 1–8. [Epub ahead of print]
29. Chan JM, Darke AK, Penney KL et al. Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Cancer Epidemiol Biomarkers Pre 2016. pii: cebp.0104.2016. [Epub ahead of print]
30. Magri V, Marras E, Restelli A et al. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 2015; 9 (3): 658–66. Epub 2014 Dec 19.
31. Kim HW, Ha US, Woo JC et al. Preventive effect of selenium on chronic bacterial prostatitis. J Infect Chemother 2012; 18 (1): 30–4. doi: 10.1007/s10156-011-0276-4
32. Попова В.В., Кожин А.И., Афонин А.А. и др. Комплексная терапия функциональной задержки полового развития у мальчиков-подростков. Врач. 2015; 3: 50–3. / Popova V.V., Kozhin A.I., Afonin A.A. i dr. Kompleksnaia terapiia funktsional'noi zaderzhki polovogo razvitiia u mal'chikov-podrostkov. Vrach. 2015; 3: 50–3. [in Russian]
33. Неймарк А.И., Клепикова И.И. Применение препарата Cелцинк плюс у мужчин с нарушением фертильности. Андрология и генитальная хирургия. 2013; 4: 77–80. / Neimark A.I., Klepikova I.I. Primenenie preparata Celtsink plius u muzhchin s narusheniem fertil'nosti. Andrologiia i genital'naia khirurgiia. 2013; 4: 77–80. [in Russian]
34. Сивков А.В., Ощепков В.Н., Евдокимов В.В. и др. Применение препарата Селцинк Плюс у больных хроническим неинфекционным простатитом и нарушениями фертильности. Урология. 2011; 5: 27–33. / Sivkov A.V., Oshchepkov V.N., Evdokimov V.V. i dr. Primenenie preparata Seltsink Plius u bol'nykh khronicheskim neinfektsionnym prostatitom i narusheniiami fertil'nosti. Urologiia. 2011; 5: 27–33. [in Russian]
2. Kulchavenya E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
3. Zhukova I.I., Kulchavenya E.V., Kholtobin D.P. Tuberkulez mochepolovoi sistemy segodnia. Urologiia. 2013; 1: 13–6. [in Russian]
4. Goodarzi D, Cyrus A, Baghinia MR et al. The efficacy of zinc for treatment of chronic prostatitis. Acta Med Indones 2013; 45 (4): 259–64.
5. Ludwig M, Dimitrakov J, Diemer T et al. Prostatitis syndrome. Changes in the ejaculate and effects on fertility. Urologe A 2001; 40 (1): 18–23.
6. Cai T, Wagenlehner FM, Mondaini N et al. Effect of human papillomavirus and Chlamydia trachomatis co-infection on sperm quality in young heterosexual men with chronic prostatitis-related symptoms. BJU Int 2014; 113 (2): 281–7. doi: 10.1111/bju.12244
7. Ivanov IB, Gritsenko VA, Kuzmin MD. Phenotypic differences between coagulase-negative staphylococci isolated from seminal fluid of healthy men and men suffering from chronic prostatitis syndrome. Int J Androl 2010; 33 (3): 563–7. doi: 10.1111/j.1365-2605.2009.00969.x
8. Dohle GR. Inflammatory-associated obstructions of the male reproductive tract. Andrologia 2003; 35 (5): 321–4.
9. Zhao H, Shen JH, Chen YP et al. Changes of seminal parameters, zinc concentration and antibacterial activity in patients with non-inflammatory chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue 2008; 14 (6): 530–2.
10. Flibotte JJ, Lee GE, Buser GL et al. Infertility, in vitro fertilization and congenital tuberculosis. J Perinatol 2013; 33 (7): 565–8. doi: 10.1038/jp.2012.146
11. Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev 2013; 8: CD009071. doi: 10.1002/14651858.CD009071.pub2
12. Yanushpolsky EH, Politch JA, Hill JA, Anderson DJ. Is leukocytospermia clinically relevant? Fertil Steril 1996; 66 (5): 822–5.
13. Domes T, Lo KC, Grober ED et al. The incidence and effect of bacteriospermia and elevated seminal leukocytes on semen parameters. Fertil Steril 2012; 97 (5): 1050–5. doi: 10.1016/j.fertnstert.2012.01.124
14. Kulchavenya E.V., Neimark A.I. Prostatit. Diagnostika i lechenie: rukovodstvo. M.: GEOTAR-Media, 2010. [in Russian]
15. Kulchavenya E. Best practice in the diagnosis and management of Urogenital Tuberculosis. Ther Adv Urol 2013; 5 (3): 143–51. doi: 10.1177/1756287213476128
16. Kulchavenya E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
17. Mirone M, Giannetta E, Isidori AM. Selenium and reproductive function. A systematic review. J Endocrinol Invest 2013; 36 (10 Suppl): 28–36.
18. Walczak-Jedrzejowska R, Wolski JK, Slowikowska-Hilczer J. The role of oxidative stress and antioxidants in male fertility. Cent European J Urol 2013; 66 (1): 60–7. doi: 10.5173/ceju.2013.01.art19
19. Mokhireva L.V., Bogadel'nikova I.V. Biologicheskaia rol' tsinka v organizme cheloveka. Tuberkulez i bolezni legkikh. 2011; 7: 3–10. [in Russian]
20. Lombardo F, Fiducia M, Lunghi R et al. Effects of a dietary supplement on chronic pelvic pain syndrome (Category IIIA), leucocytospermia and semen parameters. Andrologia 2012; 44 (Suppl. 1): 672–8. doi: 10.1111/j.1439-0272.2011.01248.x
21. Witkowska-Zimny M, Gunerka A, Wietrak E et al. Verification of the effectiveness of the dietary supplementation in infertility treatment. Pol Merkur Lekarski 2013; 35 (210): 347–51.
22. Eslamian G, Amirjannati N, Rashidkhani B et al. Nutrient patterns and asthenozoospermia: a case-control study. Andrologia 2016. doi: 10.1111/and.12624. [Epub ahead of print]
23. Ansar S, Abudawood M, Hamed SS, Aleem MM. Sodium Selenite Protects Against Silver Nanoparticle-Induced Testicular Toxicity and Inflammation. Biol Trace Elem Res 2016. [Epub ahead of print]
24. Russo A, Capogrosso P, La Croce G et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf 2016 Jun 1: 1–10. [Epub ahead of print]
25. Zhu C, Ling Q, Cai Z et al. Selenium (Se) containing phycocyanin from Se-enriched Spirulina platensis reduces inflammation in DSS-induced colitis by inhibiting NF-κB activation. J Agric Food Chem 2016. [Epub ahead of print]
26. Amin KA, Hashem KS, Alshehri FS et al. Antioxidant and Hepatoprotective Efficiency of Selenium Nanoparticles Against Acetaminophen-Induced Hepatic Damage. Biol Trace Elem Res 2016. [Epub ahead of print]
27. Bierla K, Flis-Borsuk A, Suchocki P et al. Speciation of selenium in selenium-enriched sunflower oil by HPLC-ICP MS/electrospray – Orbitrap MS/MS. J Agric Food Chem 2016. [Epub ahead of print]
28. Sun JW, Shu XO, Li HL et al. Dietary selenium intake and mortality in two population-based cohort studies of 133 957 Chinese men and women. Public Health Nutr. 2016 May 20: 1–8. [Epub ahead of print]
29. Chan JM, Darke AK, Penney KL et al. Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Cancer Epidemiol Biomarkers Pre 2016. pii: cebp.0104.2016. [Epub ahead of print]
30. Magri V, Marras E, Restelli A et al. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 2015; 9 (3): 658–66. Epub 2014 Dec 19.
31. Kim HW, Ha US, Woo JC et al. Preventive effect of selenium on chronic bacterial prostatitis. J Infect Chemother 2012; 18 (1): 30–4. doi: 10.1007/s10156-011-0276-4
32. Popova V.V., Kozhin A.I., Afonin A.A. i dr. Kompleksnaia terapiia funktsional'noi zaderzhki polovogo razvitiia u mal'chikov-podrostkov. Vrach. 2015; 3: 50–3. [in Russian]
33. Neimark A.I., Klepikova I.I. Primenenie preparata Celtsink plius u muzhchin s narusheniem fertil'nosti. Andrologiia i genital'naia khirurgiia. 2013; 4: 77–80. [in Russian]
34. Sivkov A.V., Oshchepkov V.N., Evdokimov V.V. i dr. Primenenie preparata Seltsink Plius u bol'nykh khronicheskim neinfektsionnym prostatitom i narusheniiami fertil'nosti. Urologiia. 2011; 5: 27–33. [in Russian]
2. Кульчавеня Е.В., Брижатюк Е.В., Ковешникова Е.Ю., Свешникова Н.Н. Новые тенденции в эпидемической ситуации по туберкулезу экстраторакальных локализаций в Сибири и на Дальнем Востоке. Туберкулез и болезни легких. 2009; 10: 27–31. / Kulchavenya E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
3. Жукова И.И., Кульчавеня Е.В., Холтобин Д.П. Туберкулез мочеполовой системы сегодня. Урология. 2013; 1: 13–6. / Zhukova I.I., Kulchavenya E.V., Kholtobin D.P. Tuberkulez mochepolovoi sistemy segodnia. Urologiia. 2013; 1: 13–6. [in Russian]
4. Goodarzi D, Cyrus A, Baghinia MR et al. The efficacy of zinc for treatment of chronic prostatitis. Acta Med Indones 2013; 45 (4): 259–64.
5. Ludwig M, Dimitrakov J, Diemer T et al. Prostatitis syndrome. Changes in the ejaculate and effects on fertility. Urologe A 2001; 40 (1): 18–23.
6. Cai T, Wagenlehner FM, Mondaini N et al. Effect of human papillomavirus and Chlamydia trachomatis co-infection on sperm quality in young heterosexual men with chronic prostatitis-related symptoms. BJU Int 2014; 113 (2): 281–7. doi: 10.1111/bju.12244
7. Ivanov IB, Gritsenko VA, Kuzmin MD. Phenotypic differences between coagulase-negative staphylococci isolated from seminal fluid of healthy men and men suffering from chronic prostatitis syndrome. Int J Androl 2010; 33 (3): 563–7. doi: 10.1111/j.1365-2605.2009.00969.x
8. Dohle GR. Inflammatory-associated obstructions of the male reproductive tract. Andrologia 2003; 35 (5): 321–4.
9. Zhao H, Shen JH, Chen YP et al. Changes of seminal parameters, zinc concentration and antibacterial activity in patients with non-inflammatory chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue 2008; 14 (6): 530–2.
10. Flibotte JJ, Lee GE, Buser GL et al. Infertility, in vitro fertilization and congenital tuberculosis. J Perinatol 2013; 33 (7): 565–8. doi: 10.1038/jp.2012.146
11. Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev 2013; 8: CD009071. doi: 10.1002/14651858.CD009071.pub2
12. Yanushpolsky EH, Politch JA, Hill JA, Anderson DJ. Is leukocytospermia clinically relevant? Fertil Steril 1996; 66 (5): 822–5.
13. Domes T, Lo KC, Grober ED et al. The incidence and effect of bacteriospermia and elevated seminal leukocytes on semen parameters. Fertil Steril 2012; 97 (5): 1050–5. doi: 10.1016/j.fertnstert.2012.01.124
14. Кульчавеня Е.В., Неймарк А.И. Простатит. Диагностика и лечение: руководство. М.: ГЭОТАР-Медиа, 2010. / Kulchavenya E.V., Neimark A.I. Prostatit. Diagnostika i lechenie: rukovodstvo. M.: GEOTAR-Media, 2010. [in Russian]
15. Kulchavenya E. Best practice in the diagnosis and management of Urogenital Tuberculosis. Ther Adv Urol 2013; 5 (3): 143–51. doi: 10.1177/1756287213476128
16. Кульчавеня Е.В., Бреусов А.А. Эффективность уро-ваксома при рецидивирующих инфекционно-воспалительных заболеваниях мочеполовой системы. Урология. 2011; 4: 7–11. / Kulchavenya E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
17. Mirone M, Giannetta E, Isidori AM. Selenium and reproductive function. A systematic review. J Endocrinol Invest 2013; 36 (10 Suppl): 28–36.
18. Walczak-Jedrzejowska R, Wolski JK, Slowikowska-Hilczer J. The role of oxidative stress and antioxidants in male fertility. Cent European J Urol 2013; 66 (1): 60–7. doi: 10.5173/ceju.2013.01.art19
19. Мохирева Л.В., Богадельникова И.В. Биологическая роль цинка в организме человека. Туберкулез и болезни легких. 2011; 7: 3–10. / Mokhireva L.V., Bogadel'nikova I.V. Biologicheskaia rol' tsinka v organizme cheloveka. Tuberkulez i bolezni legkikh. 2011; 7: 3–10. [in Russian]
20. Lombardo F, Fiducia M, Lunghi R et al. Effects of a dietary supplement on chronic pelvic pain syndrome (Category IIIA), leucocytospermia and semen parameters. Andrologia 2012; 44 (Suppl. 1): 672–8. doi: 10.1111/j.1439-0272.2011.01248.x
21. Witkowska-Zimny M, Gunerka A, Wietrak E et al. Verification of the effectiveness of the dietary supplementation in infertility treatment. Pol Merkur Lekarski 2013; 35 (210): 347–51.
22. Eslamian G, Amirjannati N, Rashidkhani B et al. Nutrient patterns and asthenozoospermia: a case-control study. Andrologia 2016. doi: 10.1111/and.12624. [Epub ahead of print]
23. Ansar S, Abudawood M, Hamed SS, Aleem MM. Sodium Selenite Protects Against Silver Nanoparticle-Induced Testicular Toxicity and Inflammation. Biol Trace Elem Res 2016. [Epub ahead of print]
24. Russo A, Capogrosso P, La Croce G et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf 2016 Jun 1: 1–10. [Epub ahead of print]
25. Zhu C, Ling Q, Cai Z et al. Selenium (Se) containing phycocyanin from Se-enriched Spirulina platensis reduces inflammation in DSS-induced colitis by inhibiting NF-κB activation. J Agric Food Chem 2016. [Epub ahead of print]
26. Amin KA, Hashem KS, Alshehri FS et al. Antioxidant and Hepatoprotective Efficiency of Selenium Nanoparticles Against Acetaminophen-Induced Hepatic Damage. Biol Trace Elem Res 2016. [Epub ahead of print]
27. Bierla K, Flis-Borsuk A, Suchocki P et al. Speciation of selenium in selenium-enriched sunflower oil by HPLC-ICP MS/electrospray – Orbitrap MS/MS. J Agric Food Chem 2016. [Epub ahead of print]
28. Sun JW, Shu XO, Li HL et al. Dietary selenium intake and mortality in two population-based cohort studies of 133 957 Chinese men and women. Public Health Nutr. 2016 May 20: 1–8. [Epub ahead of print]
29. Chan JM, Darke AK, Penney KL et al. Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Cancer Epidemiol Biomarkers Pre 2016. pii: cebp.0104.2016. [Epub ahead of print]
30. Magri V, Marras E, Restelli A et al. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 2015; 9 (3): 658–66. Epub 2014 Dec 19.
31. Kim HW, Ha US, Woo JC et al. Preventive effect of selenium on chronic bacterial prostatitis. J Infect Chemother 2012; 18 (1): 30–4. doi: 10.1007/s10156-011-0276-4
32. Попова В.В., Кожин А.И., Афонин А.А. и др. Комплексная терапия функциональной задержки полового развития у мальчиков-подростков. Врач. 2015; 3: 50–3. / Popova V.V., Kozhin A.I., Afonin A.A. i dr. Kompleksnaia terapiia funktsional'noi zaderzhki polovogo razvitiia u mal'chikov-podrostkov. Vrach. 2015; 3: 50–3. [in Russian]
33. Неймарк А.И., Клепикова И.И. Применение препарата Cелцинк плюс у мужчин с нарушением фертильности. Андрология и генитальная хирургия. 2013; 4: 77–80. / Neimark A.I., Klepikova I.I. Primenenie preparata Celtsink plius u muzhchin s narusheniem fertil'nosti. Andrologiia i genital'naia khirurgiia. 2013; 4: 77–80. [in Russian]
34. Сивков А.В., Ощепков В.Н., Евдокимов В.В. и др. Применение препарата Селцинк Плюс у больных хроническим неинфекционным простатитом и нарушениями фертильности. Урология. 2011; 5: 27–33. / Sivkov A.V., Oshchepkov V.N., Evdokimov V.V. i dr. Primenenie preparata Seltsink Plius u bol'nykh khronicheskim neinfektsionnym prostatitom i narusheniiami fertil'nosti. Urologiia. 2011; 5: 27–33. [in Russian]
________________________________________________
2. Kulchavenya E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
3. Zhukova I.I., Kulchavenya E.V., Kholtobin D.P. Tuberkulez mochepolovoi sistemy segodnia. Urologiia. 2013; 1: 13–6. [in Russian]
4. Goodarzi D, Cyrus A, Baghinia MR et al. The efficacy of zinc for treatment of chronic prostatitis. Acta Med Indones 2013; 45 (4): 259–64.
5. Ludwig M, Dimitrakov J, Diemer T et al. Prostatitis syndrome. Changes in the ejaculate and effects on fertility. Urologe A 2001; 40 (1): 18–23.
6. Cai T, Wagenlehner FM, Mondaini N et al. Effect of human papillomavirus and Chlamydia trachomatis co-infection on sperm quality in young heterosexual men with chronic prostatitis-related symptoms. BJU Int 2014; 113 (2): 281–7. doi: 10.1111/bju.12244
7. Ivanov IB, Gritsenko VA, Kuzmin MD. Phenotypic differences between coagulase-negative staphylococci isolated from seminal fluid of healthy men and men suffering from chronic prostatitis syndrome. Int J Androl 2010; 33 (3): 563–7. doi: 10.1111/j.1365-2605.2009.00969.x
8. Dohle GR. Inflammatory-associated obstructions of the male reproductive tract. Andrologia 2003; 35 (5): 321–4.
9. Zhao H, Shen JH, Chen YP et al. Changes of seminal parameters, zinc concentration and antibacterial activity in patients with non-inflammatory chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue 2008; 14 (6): 530–2.
10. Flibotte JJ, Lee GE, Buser GL et al. Infertility, in vitro fertilization and congenital tuberculosis. J Perinatol 2013; 33 (7): 565–8. doi: 10.1038/jp.2012.146
11. Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev 2013; 8: CD009071. doi: 10.1002/14651858.CD009071.pub2
12. Yanushpolsky EH, Politch JA, Hill JA, Anderson DJ. Is leukocytospermia clinically relevant? Fertil Steril 1996; 66 (5): 822–5.
13. Domes T, Lo KC, Grober ED et al. The incidence and effect of bacteriospermia and elevated seminal leukocytes on semen parameters. Fertil Steril 2012; 97 (5): 1050–5. doi: 10.1016/j.fertnstert.2012.01.124
14. Kulchavenya E.V., Neimark A.I. Prostatit. Diagnostika i lechenie: rukovodstvo. M.: GEOTAR-Media, 2010. [in Russian]
15. Kulchavenya E. Best practice in the diagnosis and management of Urogenital Tuberculosis. Ther Adv Urol 2013; 5 (3): 143–51. doi: 10.1177/1756287213476128
16. Kulchavenya E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
17. Mirone M, Giannetta E, Isidori AM. Selenium and reproductive function. A systematic review. J Endocrinol Invest 2013; 36 (10 Suppl): 28–36.
18. Walczak-Jedrzejowska R, Wolski JK, Slowikowska-Hilczer J. The role of oxidative stress and antioxidants in male fertility. Cent European J Urol 2013; 66 (1): 60–7. doi: 10.5173/ceju.2013.01.art19
19. Mokhireva L.V., Bogadel'nikova I.V. Biologicheskaia rol' tsinka v organizme cheloveka. Tuberkulez i bolezni legkikh. 2011; 7: 3–10. [in Russian]
20. Lombardo F, Fiducia M, Lunghi R et al. Effects of a dietary supplement on chronic pelvic pain syndrome (Category IIIA), leucocytospermia and semen parameters. Andrologia 2012; 44 (Suppl. 1): 672–8. doi: 10.1111/j.1439-0272.2011.01248.x
21. Witkowska-Zimny M, Gunerka A, Wietrak E et al. Verification of the effectiveness of the dietary supplementation in infertility treatment. Pol Merkur Lekarski 2013; 35 (210): 347–51.
22. Eslamian G, Amirjannati N, Rashidkhani B et al. Nutrient patterns and asthenozoospermia: a case-control study. Andrologia 2016. doi: 10.1111/and.12624. [Epub ahead of print]
23. Ansar S, Abudawood M, Hamed SS, Aleem MM. Sodium Selenite Protects Against Silver Nanoparticle-Induced Testicular Toxicity and Inflammation. Biol Trace Elem Res 2016. [Epub ahead of print]
24. Russo A, Capogrosso P, La Croce G et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf 2016 Jun 1: 1–10. [Epub ahead of print]
25. Zhu C, Ling Q, Cai Z et al. Selenium (Se) containing phycocyanin from Se-enriched Spirulina platensis reduces inflammation in DSS-induced colitis by inhibiting NF-κB activation. J Agric Food Chem 2016. [Epub ahead of print]
26. Amin KA, Hashem KS, Alshehri FS et al. Antioxidant and Hepatoprotective Efficiency of Selenium Nanoparticles Against Acetaminophen-Induced Hepatic Damage. Biol Trace Elem Res 2016. [Epub ahead of print]
27. Bierla K, Flis-Borsuk A, Suchocki P et al. Speciation of selenium in selenium-enriched sunflower oil by HPLC-ICP MS/electrospray – Orbitrap MS/MS. J Agric Food Chem 2016. [Epub ahead of print]
28. Sun JW, Shu XO, Li HL et al. Dietary selenium intake and mortality in two population-based cohort studies of 133 957 Chinese men and women. Public Health Nutr. 2016 May 20: 1–8. [Epub ahead of print]
29. Chan JM, Darke AK, Penney KL et al. Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Cancer Epidemiol Biomarkers Pre 2016. pii: cebp.0104.2016. [Epub ahead of print]
30. Magri V, Marras E, Restelli A et al. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 2015; 9 (3): 658–66. Epub 2014 Dec 19.
31. Kim HW, Ha US, Woo JC et al. Preventive effect of selenium on chronic bacterial prostatitis. J Infect Chemother 2012; 18 (1): 30–4. doi: 10.1007/s10156-011-0276-4
32. Popova V.V., Kozhin A.I., Afonin A.A. i dr. Kompleksnaia terapiia funktsional'noi zaderzhki polovogo razvitiia u mal'chikov-podrostkov. Vrach. 2015; 3: 50–3. [in Russian]
33. Neimark A.I., Klepikova I.I. Primenenie preparata Celtsink plius u muzhchin s narusheniem fertil'nosti. Andrologiia i genital'naia khirurgiia. 2013; 4: 77–80. [in Russian]
34. Sivkov A.V., Oshchepkov V.N., Evdokimov V.V. i dr. Primenenie preparata Seltsink Plius u bol'nykh khronicheskim neinfektsionnym prostatitom i narusheniiami fertil'nosti. Urologiia. 2011; 5: 27–33. [in Russian]
Авторы
Е.В.Кульчавеня*1,2, А.В.Осадчий1
1 ФГБУ Новосибирский НИИ туберкулеза Минздрава России. 630040, Россия, Новосибирск, ул. Охотская, д. 81а;
2 ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России. 630091, Россия, Новосибирск, Красный пр-т, д. 52
*urotub@yandex.ru
1 ФГБУ Новосибирский НИИ туберкулеза Минздрава России. 630040, Россия, Новосибирск, ул. Охотская, д. 81а;
2 ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России. 630091, Россия, Новосибирск, Красный пр-т, д. 52
*urotub@yandex.ru
________________________________________________
E.V.Kulchavenya*1,2, A.V.Osadchiy1
1 Novosibirsk Research Institute of Tuberculosis of the Ministry of Health of the Russian Federation. 630040, Russian Federation, Novosibirsk, ul. Okhotskaia, d. 81a;
2 Novosibirsk State Medical University of the Ministry of Health of the Russian Federation. 630091, Russian Federation, Novosibirsk, Krasnyi pr-t, d. 52
*urotub@yandex.ru
1 Novosibirsk Research Institute of Tuberculosis of the Ministry of Health of the Russian Federation. 630040, Russian Federation, Novosibirsk, ul. Okhotskaia, d. 81a;
2 Novosibirsk State Medical University of the Ministry of Health of the Russian Federation. 630091, Russian Federation, Novosibirsk, Krasnyi pr-t, d. 52
*urotub@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.